Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans

Drug Metabolism and Disposition

Volumn 24, Issue 12, 1996, Pages 1389-1394

  Balani, Suresh K ^a   Woolf, Eric J ^a   Hoagland, Vicki L ^a   Sturgill, Marc G ^b   Deutsch, Paul J ^a   Yeh, Kuang C ^a   Lin, Jiunn H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Robert Wood Johnson Clin Res Ctr   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; GLUCURONIDE; INDINAVIR; PROTEINASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DOG; DRUG ABSORPTION; DRUG DISPOSITION; DRUG FECES LEVEL; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INTRAGASTRIC DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MASS SPECTROMETRY; MONKEY; NONHUMAN; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ADULT; ANIMALS; AREA UNDER CURVE; BILE; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; DOGS; FECES; FEMALE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; MALE; MASS SPECTROMETRY; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; SPECTROPHOTOMETRY, ULTRAVIOLET;

CANIS FAMILIARIS; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIMATES;

EID: 0030467480     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. W. A. Haseltine: Molecular biology of HIV-1. In "AIDS. Etiology, Diagnosis, Treatment and Prevention" (V. T. DeVita, S. Hellman, S. A. Rosenberg, J. Curran, M. Essex, and A. S. Fauci, eds.), pp. 39-59. J. P. Lippincott Company, Philadelphia, 1992.
2. L. Ratner, W. Haseltine, R. Patarca, K. J. Livak, B. Starcich, S. F. Josephs, E. R. Doran, J. A. Ragalski, E. A. Whitehom, K. Baumeister, L. Ivanoff, S. R. Petteway, M. L. Pearson, J. A. Lautenberger, T. S. Papas, J. Ghrayeb, N. T. Chang, R. C. Gallo, and F. Wong-Stall: Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 313, 277-284 (1985).
3. J. A. Levy (ed.): "HIV and the Pathogenesis of AIDS," pp. 1-33. A. S. M. Press, Washington, D.C., 1994.
4. L. Montagnier, J. Chermann, F. Barre-Sinoussi, S. Chamaret, J. Gruest, M. T. Nugeyre, F. Rey, C. Dauguet, C. Axler-Blin, F. Vezinet-Brun, C. Rourioux, A. G. Saimot, W. Rozenbaum, J. C. Gluckman, D. Klatzmann, E. Vilmer, C. Grisclli, C. Gazengel, and J. B. Brunet: A new human T-lymphotropic retrovirus: characterization and possible role in lymphadenopathy and acquired immune deficiency syndrome. In "Human T-Cell Leukemia/Lymphoma Virus" (R. C. Gallo, M. E. Essex, and L. Gross, eds.), pp. 363-379. Cold Spring Harbor, NY, 1984.
5. A. M. Skalka: Retroviral proteases: first glimpses at the anatomy of a processing machine. Cell 56, 911-913 (1989).
6. J. M. Louis, N. T. Hashed, K. D. Parris, A. R. Kimmel, and D. M. Jerina: Kinetics and mechanism of autoprocessing of human immunodeficiency virus type 1 protease from an analog of the Gag-Pol polyprotein. Proc. Natl. Acad. Sci. U.S.A. 91, 7970-7974 (1994).
7. J. R. Huff: HIV protease: a novel chemotherapeutic target for AIDS. J. Med. Chem. 34, 2305-2314 (1991).
8. J. P. Vacca, B. D. Dorsey, W. A. Schleif, R. B. Levin, S. L. McDaniel, P. L. Darke, J. Zugay, J. C. Quintero, O. M. Blahy, E. Roth, V. V. Sardana, A. J. Schlabach, P. I. Graham, J. H. Condra, L. Gotlib, M. K. Holloway, J. Lin, I.-W. Chen, K. Vastag, D. Ostovic, P. S. Anderson, E. A. Emini, and J. R. Huff: L-735,524: an orally bioavailable HIV-1 protease inhibitor. Proc. Natl. Acad. Sci. U.S.A. 91, 4096-4100 (1994).
9. J. R. Huff, J. R. Vacca, B. D. Dorsey, E. A. Emini, J. H. Condra, W. A. Schleif, F. E. Massari, P. J. Deutsch, J. Chodakewitz, L. C. Kuo, and Z. Chen: Presented at the 211th National Meeting of the American Chemical Society, New Orleans, LA, March 24, 1996, Abstract Medi-255.
10. S. K. Balani, B. H. Arison, L. Mathai, L. R. Kauffman, R. R. Miller, R. A. Stearns, I.-W. Chen, and J. H. Lin: Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine. Drug Metab. Dispos. 23, 266-270 (1995).
11. E. Woolf, T. Au., H. Haddix, and B. Matuszewski: Determination of L-735,524, a human immunodeficiency virus protease inhibitor, in human plasma and urine via high performance liquid chromatography with column switching. J. Chromatogr. 692, 45-52 (1995).
12. M. L. Rocci and W. J. Jusko: LAGRAN program for area and moments in pharmacokinetic analysis. Comp. Prog. Biomed. 16, 203-216 (1983).
13. B. S. Drasar and M. J. Hill (eds.): "Human Intestinal Flora," pp. 54-57. Academic Press, New York, 1974.
14. P. R. Steinmetz and C. Balko: Therapeutic implications of the intestinal microflora. N. Engl. J. Med. 289, 623-628 (1973).
15. J. H. Lin, I.-W. Chen, K. J. Vastag, and D. Ostovic: pH-dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs. Drug Metab. Dispos. 23, 730-735 (1995).
16. J. H. Lin, M. Chiba, S. K. Balani, I.-W. Chen, G. Y.-S. Kwei, K. J. Vastag, and J. A. Nishime: Species differences in the pharmacokinetics and metabolism of indinavir, a potent protease inhibitor. Drug Metab. Dispos. 24, 1111-1120, 1996.
17. M. Chiba, M. Hensleigh, J. A. Nishime, S. K. Balani, and J. H. Lin: Role of CYP 3A4 in human metabolism of MK-639, a potent HIV protease inhibitor. Drug Metab. Dispos. 24, 307-314 (1996).
18. L. J. Fisher, R. L. Thies, D. Charkowski, and K. J. Donham: Formation and urinary excretion of cyproheptadine glucuronide in monkeys, chimpanzees and humans. Drug Metab. Dispos. 8, 422-424 (1980).
19. W. R. Rush, O. F. Alexander, D. J. Hall, R. J. Dow, L. Tokes, L. Kurz, and D. J. M. Graham: The metabolism of nafimidone hydrochloride in the dog, primates and man. Xenobiotica 20, 123-132 (1990).
20. F. W. Janssen, S. K. Kirkman, C. Fenselau, M. Stogniew, B. R. Hofmann, E. M. Young, and H. W. Ruelins: Metabolic formation of N- and O-glucuronides of 3-(p-chlorophenyl)thiazolo[3,2-a]benzimidazole-2-acetic acid. Rearrangement of the 1-0-acylglucuronide. Drug Metab. Dispos. 10, 599-604 (1982).
21. A. Rubin, P. H. Dhahir, R. E. Crabtree, and D. P. Henry: The disposition of I-3-[(dimethylamino)-(m-dioxan-5-yl)methyl]pyridine in man. Drug Metab. Dispos. 7, 149-154 (1979).
22. L. P. C. Delbressine, M. E. G. Moonen, F. M. Kaspersen, P. L. Jacobs, and G. L. Wagenaars: Biotransformation of mianserin in laboratory animals and man. Xenobiotica 22, 227-236 (1992).
23. N. K. Chaudhuri, O. A. Servando, M. J. Manniello, R. C. Luders, D. K. Chao, and M. F. Bartlett: Metabolism of tripelennamine in man. Drug Metab. Dispos. 4, 372-378 (1976).
24. K. Kawahara, T. Awaji, K. Uda, Y. Sakai, and Y. Hashimoto: Urinary excretion of conjugates of dothiepin and northiaden (mono-N-demethyldothiepin) after an oral dose of dothiepin to humans. Eur. J. Drug Metab. Pharm. 11, 29-32 (1986).
25. 1-antihistamine in humans. Xenobiotica 21, 1281-1288 (1991).
26. M. W. Sinz and R. P. Remmel: Isolation and characterization of a novel quaternary ammonium glucuronide of lamotrigine. Drug Metab. Dispos. 19, 149-153 (1991).
27. M. Nishikata, A. Nomura, K. J. Iseki, K. Miyazaki, A. Nakai, H. Fushida, K. Miyake, and T. Arita: Enantioselective pharmacokinetics of homochlorcyclizine. II. Disposition and metabolism of (+)-,(-)- and race-mic homochlorcyclizine after oral administration to man. Eur. J. Clin. Pharm. 43, 533-538 (1992).
28. U. B. Pfaff, B. Becher, E. Nusser, K. Nill, B. B. Weber, D. Zaunbrecher, H. Washsmuth, and A. Prox: Quaternary N-glucuronides of 10-hydroxylated amitriptyline metabolites in human urine. Xenobiotica 20, 727-738 (1990).
29. H. Luo, E. M. Hawes, G. McKay, E. D. Korchiuski, and K. K. Midha: The quaternary ammonium-linked glucuronides of doxepin: a major metabolite in depressed patients treated with doxepin. Drug Metab. Dispos. 19, 722-724 (1991).
30. H. B. Hucker, S. C. Stauffer, A. J. Balletto, S. D. White, A. G. Zaccei, and B. H. Arison: Physiological disposition and metabolism of cyclobenzaprine in rat, dog, rhesus monkey and man. Drug Metab. Dispos. 6, 659-672 (1978).
31. +-glucuronidation of aliphatic tertiary amines in human: antidepressant versus antipsychotic drugs. Xenobiotica 25, 291-301 (1995).
32. B. Burchell, T. Ebner, R. Wooster, and L. Sutherland: Analysis of the specificity of human liver glucuronidation using cloned and stably expressed UDP-glucuronosyltransferases. In "Human Drug Metabolism" (E. H. Jeffery, ed.), pp. 89-99. CRC Press, Boca Raton, FL, 1992 (and references therein).
33. J. F. Bigot, J. M. Begue, J. R. Kiechel, and A. Guillouzo: Species differences in metabolism of ketotifen in rat, rabbit and man: demonstration of similar pathways in vivo and in cultured hepatocytes. Life Sci. 40, 883-890 (1987).
34. P. V. Macrae, M. Kinns, F. S. Pullen, and M. H. Tarbit: Characterization of quaternary N-glucuronide metabolite of the imidazole antifungal, tioconazole. Drug Metab. Dispos. 18, 1100-1102 (1990).
35. A. Bieder, B. Decouvelaere, C. Gaillard, H. Depaire, D. Heusse, C. Ledoux, M. Lemar, J. P. Le Roy, L. Raynand, C. Snozzi and J. Gregoire: Comparison of the metabolism of oltipraz in the mouse, rat, and monkey and in man. Arzneim.-Forsch/Drug Res. 33, 1289-1297 (1983).
36. R. P. Remmel and M. W. Sinz: A quaternary ammonium glucuronide is the major metabolite of lamotrigine in guinea pigs. In-vitro and in-vivo studies. Drug. Metab. Dispos. 19, 630-636 (1991).
37. J. P. Lehman, C. Fenselau, and J. R. Depaulo: Quaternary ammonium-linked glucuronides of amitriptylin, imipramine and chlorpromazine. Drug Metab. Dispos. 11, 221-225 (1983).
38. J. P. Lehman and C. Fenselau: Synthesis of quaternary ammonium-linked glucuronides by rabbit hepatic microsomal UDP-glucuronyltransferase and analysis by fast-atom bombardment mass spectrometry. Drug Metab. Dispos. 10, 446-449 (1982).
39. M. D. Green, W. P. Bishop, and T. R. Tephly: Expressed human UGT1.4 protein catalyzes the formation of quaternary ammonium-linked glucuronides. Drug Metab. Dispos. 23, 299-302 (1995).
40. M. D. Green and T. R. Tephly: Glucuronidation of amines and hydroxylated xenobiotics and endobiotics catalyzed by expressed human UGT1.4 protein. Drug Metab. Dispos. 24, 356-363 (1996).
41. R. Gulick, J. Mellors, D. Havlir, J. Eron, C. Gonzalez, D. McMahon, D. Richman, F. Valentine, L. Jonas, A. Meibohm, R. Chiou, P. Deutsch, E. Emini, and J. Chodakewitz: Potent and sustained antiretroviral activity of indinavir (IDV) in combination with zidovudine (ZDV) and lamivudine (3TC). Third National Conference on Human Retroviruses and Related Infections, Washington, D.C., January 29, 1996, p. 162, (abstract).